125 related articles for article (PubMed ID: 1654481)
1. Pharmacological and physicochemical properties of a new anthracycline with potent antileukemic activity.
Nafziger J; Auclair C; Florent JC; Guillosson JJ; Monneret C
Leuk Res; 1991; 15(8):709-13. PubMed ID: 1654481
[TBL] [Abstract][Full Text] [Related]
2. 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro.
Perchellet EM; Magill MJ; Huang X; Dalke DM; Hua DH; Perchellet JP
Anticancer Drugs; 2000 Jun; 11(5):339-52. PubMed ID: 10912950
[TBL] [Abstract][Full Text] [Related]
3. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
4. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
5. Antileukemic activity of 4-demethoxydaunorubicin in mice.
Casazza AM; Pratesi G; Giuliani F; Di Marco A
Tumori; 1980 Oct; 66(5):549-64. PubMed ID: 6936969
[TBL] [Abstract][Full Text] [Related]
6. Antileukemic activity of synthetic daunomycinone derivatives bearing modifications in the glycosidic moiety.
Perchellet EM; Sperfslage BJ; McIlvain CJ; Aligiannis N; Pouli N; Marakos P; Skaltsounis AL; Perchellet JP
Anticancer Res; 2001; 21(6A):3957-67. PubMed ID: 11911277
[TBL] [Abstract][Full Text] [Related]
7. Enhanced topoisomerase II-induced DNA breaks and free radical production by a new anthracycline with potent antileukemic activity.
Andrivon W; Saucier JM; Auclair C; Monneret C; Florent JC; Guillosson JJ; Nafziger J
Leuk Res; 1996 Feb; 20(2):119-26. PubMed ID: 8628010
[TBL] [Abstract][Full Text] [Related]
8. [Models of preclinical studies of anthracyclines].
Fizames C
Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of genistein and amsacrine on leukemia cell proliferation.
Finlay GJ; Holdaway KM; Baguley BC
Oncol Res; 1994; 6(1):33-7. PubMed ID: 7919550
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability.
Kong XB; Rubin L; Chen LI; Ciszewska G; Watanabe KA; Tong WP; Sirotnak FM; Chou TC
Mol Pharmacol; 1992 Feb; 41(2):237-44. PubMed ID: 1311406
[TBL] [Abstract][Full Text] [Related]
11. A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631.
Villamarín S; Mansilla S; Ferrer-Miralles N; Priebe W; Portugal J
Eur J Biochem; 2003 Feb; 270(4):764-70. PubMed ID: 12581216
[TBL] [Abstract][Full Text] [Related]
12. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
Jensen PB; Sørensen BS; Sehested M; Demant EJ; Kjeldsen E; Friche E; Hansen HH
Biochem Pharmacol; 1993 May; 45(10):2025-35. PubMed ID: 8390259
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antitumor activity of 7-O-(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl) daunomycinone derivatives modified at C-3' or C-4'.
Takagi Y; Kobayashi N; Chang MS; Lim GJ; Tsuchiya T
Carbohydr Res; 1998 Feb; 307(3-4):217-32. PubMed ID: 9675364
[TBL] [Abstract][Full Text] [Related]
14. R17934-NSC238159: a new antitumor drug--II. Effect on mitotic cycle of L1210 leukemia cells in vivo and synergism with cytosine arabinoside (NSC63878).
Atassi G; Schaus C; Tagnon HJ
Eur J Cancer (1965); 1975 Sep; 11(9):609-14. PubMed ID: 1220976
[No Abstract] [Full Text] [Related]
15. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
McGovren JP
Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
[TBL] [Abstract][Full Text] [Related]
16. [New anthracycline antibiotics and derivatives].
Tatsuta K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
[TBL] [Abstract][Full Text] [Related]
17. Effect of various substitutions in positions 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin.
Di Marco A; Casazza AM; Soranzo C; Pratesi G
Cancer Chemother Pharmacol; 1978; 1(4):249-54. PubMed ID: 750112
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antileukemic activity of N-enamine derivatives of daunorubicin, 5-iminodaunorubicin, and doxorubicin.
Stefańska B; Dzieduszycka M; Bontemps-Gracz M; Borowski E; Martelli S
J Antibiot (Tokyo); 1988 Feb; 41(2):193-8. PubMed ID: 3356607
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of new N-substituted daunorubicin derivatives.
Mazerska Z; Woynarowska B; Stefanska B; Borowski E; Martelli S
Drugs Exp Clin Res; 1987; 13(6):345-51. PubMed ID: 3308387
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor properties of 3'-(4-morpholinyl) and 3'-(4-methoxy-1-piperidinyl) derivatives of 3'-deaminodaunorubicin.
Mosher CW; Wu HY; Fujiwara AN; Acton EM
J Med Chem; 1982 Jan; 25(1):18-24. PubMed ID: 7086816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
